


AMENDED CLAIM SET:

1. (currently amended) A urea compound derivative represented by Formula I




any of its enantiomers or any mixture of its enantiomers, or a prodrug, or a pharmaceutically-acceptable addition salt thereof, wherein

X represents O, S or $\text{NR}^{''''}$; wherein $\text{R}^{''''}$ represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl or cyano;

R' and R'' , independently of each other, both represent hydrogen, alkyl, cycloalkyl or cycloalkyl-alkyl;

R^1 represents hydrogen, alkyl, hydroxy, alkoxy, halo, haloalkyl, haloalkoxy, cyano, nitro, amino, or a group of formula $\text{NR}^{'''''}(\text{CO})\text{R}^{''''''}$, $\text{NR}^{'''''}(\text{CO})\text{Ar}$, $\text{NR}^{'''''}(\text{CO})\text{NR}^{''''''}\text{R}^{''''''}$, $\text{NR}^{'''''}(\text{CO})\text{NR}^{''''''}\text{Ar}$, $\text{NR}^{'''''}(\text{CO})\text{CH}=\text{CH}\text{R}^{''''''}$, $\text{NR}^{'''''}(\text{SO}_2)\text{R}^{''''''}$ or $\text{NR}^{'''''}(\text{SO}_2)\text{Ar}$; wherein $\text{R}^{'''''} and $\text{R}^{''''''}$, independently of each other, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, phenyl, or benzyl; and Ar represents an aryl group or an aromatic mono- or polycyclic heterocyclic group; or R^1 represents a group of formula $\text{CONR}^{'''''}\text{R}^{''''''}$ or $\text{SO}_2\text{NR}^{'''''}\text{R}^{''''''}$, wherein $\text{R}^{'''''} and $\text{R}^{''''''}$, independently of each other, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, phenyl, or benzyl; or $\text{R}^{'''''} and $\text{R}^{''''''}$ together with the nitrogen atom to which they are attached form a heterocyclic ring; or R^1 represents a group of formula$$$



R² represents hydrogen, hydroxy, halo, haloalkyl, haloalkoxy, cyano, nitro or amino;
 R³ represents hydrogen, hydroxy, halo, haloalkyl, haloalkoxy, cyano, nitro or amino;
 R⁴ represents hydrogen, alkyl, hydroxy, halo, haloalkyl, haloalkoxy, cyano, nitro or amino;
 R⁵ represents hydrogen, hydroxy, halo, haloalkyl, haloalkoxy, cyano, nitro or amino;
 R⁶ represents hydrogen, hydroxy, halo, haloalkyl, haloalkoxy, cyano, nitro, amino or phenyl;
 R⁷ represents hydrogen, hydroxy, halo, haloalkyl, haloalkoxy, cyano, nitro, amino or phenyl; and
 R⁸ represents hydrogen, hydroxy, halo, haloalkyl, haloalkoxy, alkoxy, cyano, nitro or amino.

2. – 26. (cancelled).

27. (currently amended) The urea compound derivative of claim 1 [[23]], which is
N-(3-Chloro-6-hydroxy-phenyl)-*N'*-(2-chloro-5-trifluoromethyl-phenyl)-urea;
N-(2-Amino-6-hydroxy-phenyl)-*N'*-(3-trifluoromethyl-phenyl)-urea;
N-(5-Chloro-2-hydroxy-phenyl)-*N'*-(2-hydroxy-4-nitro-phenyl)-urea;
N-(2-Amino-4,5-dichloro-phenyl)-*N'*-(2-chloro-5-trifluoromethyl-phenyl)-urea;
N-(4,5-Dichloro-2-[3-(2-chloro-5-trifluoromethyl-phenyl)-ureido]phenyl)-acetamide;
N-(3-Chloro-4-hydroxy-phenyl)-*N'*-(3-trifluoromethyl-phenyl)-urea;
N-(4-Hydroxy-6-methyl-phenyl)-*N'*-(3-trifluoromethyl-phenyl)-urea;
N-(3,5-Dichloro-4-hydroxy-phenyl)-*N'*-(3-trifluoromethyl-phenyl)-urea;
N-(2-Chloro-5-trifluoromethyl-phenyl)-*N'*-(3,5-dichloro-4-hydroxy-phenyl)-urea;
N-(Biphenyl-3-yl)-*N'*-(3,5-dichloro-4-hydroxy-phenyl)-urea;
N-(Biphenyl-4-yl)-*N'*-(3,5-dichloro-4-hydroxy-phenyl)-urea;
N-(Biphenyl-4-yl)-*N'*-(5-chloro-2-hydroxy-phenyl)-urea;
N-(3,5-Dichloro-2-hydroxy-phenyl)-*N'*-(2-chloro-5-trifluoromethyl-phenyl)-urea;
N-(3-Bromo-5-chloro-2-hydroxy-phenyl)-*N'*-(2-chloro-5-trifluoromethyl-phenyl)-urea;
N-(2-Chloro-5-trifluoromethyl-phenyl)-*N'*-(3-hydroxy-5-methyl-phenyl)-urea;
N-(3-Hydroxy-5-methyl-phenyl)-*N'*-(3-trifluoromethyl-phenyl)-urea;
N-(2-Chloro-5-trifluoromethyl-phenyl)-*N'*-(4-hydroxy-2-methyl-phenyl)-urea;
N-(5-Chloro-2-methoxy-phenyl)-*N'*-(2-chloro-5-trifluoromethyl-phenyl)-urea;

~~*N*-(2-Hydroxy-6-nitro-phenyl)-*N'*-(3-trifluoromethyl-phenyl)-urea; or
N-(3-Chloro-6-methoxy-phenyl)-*N'*-(2-hydroxy-4-nitro-phenyl)-urea;~~
or an enantiomer or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof.

28. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a urea compound derivative of claim 1, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.

29. – 37. (cancelled).

38. (cancelled).